News Conference News CRT 2025 AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years L.A. McKeown March 10, 2025
News Conference News BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years Caitlin E. Cox March 02, 2022
News Conference News CRT 2021 BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients Caitlin E. Cox March 16, 2021
News Conference News CRT 2020 BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis L.A. McKeown February 25, 2020
News Conference News CRT 2020 Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs Michael O'Riordan February 24, 2020
News Conference News CRT 2017 Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate Michael O'Riordan February 21, 2017